fbpx

Year

2013
Neurobiology If the development of our nervous system is disturbed, we risk developing serious neurological diseases, impairing our sensory systems, movement control or cognitive functions. This is true for all organisms with a well-developed nervous system, from man to worm. New research from BRIC, University of Copenhagen reveals how a tiny molecule called mir-79 regulates...
The top five candidates to compete in this year’s EuropaBio Most Innovative EU Biotech SME Award have been selected. Entering its 4th year, the award has grown rapidly each year to reach a wider audience across members states, with applications coming from all three sectors of biotechnology- healthcare, industrial and agricultural, all providing solutions to...
  Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic medications. ...
  Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today it has appointed Gregg Alton and Graham Cooper to its Board of Directors. “We are pleased to appoint Gregg and Graham to our Board of Directors,” commented Krisztina Zsebo Ph.D.,...
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that data from a pivotal animal study of CERAMENTT’BONE VOID FILLER, were published online in the Journal of Orthopaedic Surgery and Research. The aim of the study was to compare the stability of...
Veloxis Introduces Envarsus® as Trade Name for LCP-TacroT Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will be presented at the European Society for Organ Transplantation as a late-breaker oral presentation at 8:30 a.m. CEST, Sept. 9, in...
  OLFUS-VIPES will be the largest clinical study designed to assess efficacy, safety and long-term tolerance of peanut allergy treatment DBV Technologies creator of Viaskin®, a new standard in the treatment of allergy, announced today that the first patient has been enrolled in the open-label follow-up study (OLFUS) of VIPES phase IIb study to evaluate...
  Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr...
STEM CELL RESEARCH All organs in our body rely on stem cells in order to maintain their function. The skin is our largest organ and forms a shield against the environment. New research results from BRIC, University of Copenhagen and Cambridge University, challenge current stem cell models and explains how the skin is maintained throughout...
  – MYDICAR When Inhaled May Restore Function of SERCA2a Enzyme in the Lungs to Reverse Deadly PAH Condition – Celladon Corporation, a clinical-stage biotechnology company committed to applying its first-mover, leadership position in the field of SERCA enzymes to transform the lives of patients with important, life-threatening diseases, announced today that an international team...
1 2 3 4 5 7

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge